<DOC>
	<DOC>NCT02621125</DOC>
	<brief_summary>This is a double blind, randomized, placebo controlled clinical trial to test the efficacy of the antioxidant formulation Fertilix® in lowering the levels of damaged sperm DNA in men diagnosed with moderate to high Sperm Oxidative DNA Damage (SODD)</brief_summary>
	<brief_title>Fertilix Supplements and Assisted Reproductive Technology</brief_title>
	<detailed_description />
	<criteria>Males with a sperm sample containing 8OHdG levels &gt; 15% and must be capable of producing an ejaculate containing &gt;10million sperm upon study enrollment. Male is between 2055 years of age seeking treatment for infertility with his partner at URA and who is a candidate for an IUI, IVF or IVFICSI (excluding donor egg) procedure. Female is between 2042 years of age Female exhibits tubal patency on hydrosonogram or hysterosalpingogram (HSG) Female exhibits normal uterine cavity by hysteroscopy, hydrosonogram or hysterosalpingogram (HSG). Exclusion Criteria Subjects with initial semen analysis of an ejaculate containing &lt; 10 million sperm. Men who have been taking nutraceuticals, vitamins or other compounds known to have antioxidant activities within4 weeks of the study. No other supplements may be taken with Fertilix. Men who have hypersensitivity or an allergy to any of the ingredients in Fertilix®. Men who have been treated with a chemotherapeutic agent known to cause sterility, such as cyclophosphamide. Men who have taking anabolic steroids or testosterone replacement within 4 months of the study. Men currently being treated with a Ca++ channel blocker or other medical treatment known to adversely affect sperm production or function. Men with HIV, hepatitis B and C.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>